Omalizumab rescue therapy in refractory status asthmaticus.

Chetana Shanmukhappa, Sanjana; Kumar, Arun; Dey, Akash; J V S, Janani; Lokeshwaran, Srivatsa; Kumar K, Sunil; Doraiswamy, Prakash; M R, Shashank; Gayathri, Lakshmi

Chetana Shanmukhappa, Sanjana; Kumar, Arun; Dey, Akash; J V S, Janani; Lokeshwaran, Srivatsa; Kumar K, Sunil; Doraiswamy, Prakash; M R, Shashank; Gayathri, Lakshmi.

Afiliación

Chetana Shanmukhappa S; Unity Hospital, Rochester, NY, USA.
Kumar A; Department of Pharmacy, KLE College of Pharmacy, Bangalore, India.
Dey A; Department of Pharmacy, KLE College of Pharmacy, Bangalore, India.
J V S J; Department of Pharmacy, KLE College of Pharmacy, Bangalore, India.
Lokeshwaran S; Department of Pulmonology, Aster CMI Hospital, Bangalore, India.
Kumar K S; Department of Pulmonology, Aster CMI Hospital, Bangalore, India.
Doraiswamy P; Department of Anesthesiology and Critical Care, Aster CMI Hospital, Bangalore, India.
M R S; Department of Anesthesiology and Critical Care, Aster CMI Hospital, Bangalore, India.
Gayathri L; Department of Pharmacy, KLE College of Pharmacy, Bangalore, India.

J Asthma ; 60(12): 2243-2247, 2023 12.

Article en En | MEDLINE | ID: mdl-37427873

Asunto(s)

Antiasmáticos; Asma; Estado Asmático; Masculino; Humanos; Adulto; Omalizumab/uso terapéutico; Estado Asmático/tratamiento farmacológico; Anticuerpos Monoclonales Humanizados/uso terapéutico; Inmunoglobulina E; Resultado del Tratamiento

Palabras clave

Omalizumab; RSA; Refractory status asthmaticus; allergic asthma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Estado Asmático / Antiasmáticos Límite: Adult / Humans / Male Idioma: En Revista: J Asthma Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google